SELLAS Life Sciences (SLS) EBITDA Margin (2012 - 2022)
SELLAS Life Sciences (SLS) posted quarterly EBITDA Margin of 1673.5% for Q1 2022, down 163411.0% year-over-year from N/an in Q1 2021, and down 614.05% quarter-over-quarter from 234.37% in Q2 2021.
SELLAS Life Sciences (SLS) EBITDA Margin (2012 - 2022) Analysis & Trends
SELLAS Life Sciences (SLS) has reported EBITDA Margin for 7 consecutive years, with 1673.5% the latest figure, recorded in Q1 2022.
- In Q1 2022, EBITDA Margin fell 163411.0% year-over-year to 1673.5%; the TTM figure through Dec 2022 stood at 4195.0% (down 386218.0% YoY), while the FY2022 annual figure was 4195.0%, down 386218.0% from the prior year.
- EBITDA Margin fell to 1673.5% in Q1 2022 per SLS's latest filing, from 234.37% in the prior quarter.
- Across five years, EBITDA Margin topped out at 39.39% in Q1 2021 and bottomed at 1673.5% in Q1 2022.
- Historically, EBITDA Margin has averaged 541.54% across 3 years, with a median of 226.63% in 2021.
- On a YoY basis, EBITDA Margin climbed as much as 163411 bps in 2022 and fell as far as 163411 bps in 2022.
- SELLAS Life Sciences' EBITDA Margin stood at 218.89% in 2020, then decreased by 7 bps to 234.37% in 2021, then tumbled by 614 bps to 1673.5% in 2022.
- Business Quant data shows SLS's EBITDA Margin at 1673.5% in Q1 2022, 234.37% in Q2 2021, and 39.39% in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -1,673.50% |
| Jun 30, 2021 | -234.37% |
| Mar 31, 2021 | -39.39% |
| Dec 31, 2020 | -218.89% |
| Jun 30, 2015 | -268.57% |
| Mar 31, 2015 | -324.07% |
| Dec 31, 2014 | -303.38% |
| Sep 30, 2014 | -652.28% |
| Jun 30, 2014 | -677.09% |
| Mar 31, 2014 | -545.28% |
| Dec 31, 2013 | -219.06% |
| Sep 30, 2013 | -425.49% |
| Jun 30, 2013 | -342.60% |
| Mar 31, 2013 | -304.23% |
| Dec 31, 2012 | 476.75% |
| Sep 30, 2012 | -472.48% |